Aarti Drugs Chandrakant Vallabhaji Gogri steps down
Aarti Drugs (BSE: AARTIDRUGS) said Chandrakant Vallabhaji Gogri has ceased. The company is valued at about ₹4,631 crore.
What happened
Aarti Drugs (BSE: AARTIDRUGS) informed the stock exchanges on 15 November 2026 at 10:53 PM that Chandrakant Vallabhaji Gogri has ceased.
From the filing: "the Company Dear Sir / Madam, With profound grief, we inform you of the demise of Shri Chandrakant Vallabhaji Gogri, Chairman Emeritus and Promoter of the Company, today, i.e., Sunday, November 15, 2026."
Company snapshot
Aarti Drugs is a small-cap company in the Healthcare sector, with a market value of about ₹4,631 crore.
The stock last traded at ₹507.4, against a 52-week range of ₹319–₹527.5 (3.8% below the high).
Before this filing the shares had moved +26.6% over the month and +23.5% over three months. Average daily turnover over the last 20 sessions was about ₹114 crore.
Promoters held 54.07% at the end of Q2 FY27, down 0.36% points from the previous quarter; 2.51% of promoter shares were pledged. Foreign institutions owned 2.26% and domestic institutions 10.24%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q2 FY26 | 653 | 45.3 | 4.95 |
| Q3 FY26 | 602 | 40.5 | 4.44 |
| Q4 FY26 | 720 | 55.2 | 6.05 |
| Q1 FY27 | 703 | 50.2 | 5.49 |
| Q2 FY27 | 826 | 82.9 | 9.07 |
What history shows
BCEIE's records show 4 previous management change filings from the company since May 2026.
After those filings, the stock fell 1.6% on average the next trading day and was down 2.7% on average after five days (4 filings with price data).
Across 140 similar disclosures by other Healthcare companies, shares moved +1.3% on average the next day and +2.3% over five days; 52% of them rose the next day.
Market-wide, 4,563 management change filings with an impact score of 50 or more saw an average next-day move of −0.0%, with 46% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 30 Sept 2026 | Resignation of Director/KMP/SMP | −2.3% | −3.9% |
| 30 Sept 2026 | Change in Directorate/ Management | −2.3% | −3.9% |
| 26 Sept 2026 | Change in Director(s) of the company. | +0.3% | −2.9% |
| 31 Jul 2026 | Management change | −2.1% | −0.0% |
What to watch
- The appointment of a successor and any change in strategy or guidance.
In the news
Recent coverage elsewhere (links open the original publisher):
- Aarti Drugs Q2 FY27 Profit Jumps 83% on API, Formulation Growth
- Aarti Drugs Q2 Results: Net profit soars 83% on stronger margins, revenue growth
- Aarti Drugs shares defy weak market sentiment; skyrocket 11% today | Here's why; stock returns, performance
- Aarti Drugs Limited reports ₹82.77 crore Q2 PAT, ₹826.24 crore revenue
- Aarti Drugs Q2 2027 Earnings Call Is Live
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.